AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition

Alex O. Haber; Aditi Jain; Chinnadurai Mani; Avinoam Nevler; Lebaron C. Agostini; Talia Golan; Komaraiah Palle; Charles J. Yeo; William H. Gmeiner; Jonathan R. Brody

doi:10.1158/1541-7786.MCR-20-0985

Rapid Impact

AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition

Alex O. Haber, Aditi Jain, Chinnadurai Mani, Avinoam Nevler, Lebaron C. Agostini, Talia Golan, Komaraiah Palle, Charles J. Yeo, William H. Gmeiner and Jonathan R. Brody

Alex O. Haber

1The Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.

2Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Aditi Jain

1The Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.

2Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Chinnadurai Mani

3Texas Tech University Health Sciences Center, Lubbock, Texas.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Avinoam Nevler

1The Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.

2Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Avinoam Nevler

Lebaron C. Agostini

1The Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.

2Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Lebaron C. Agostini

Talia Golan

4Oncology Institute, Chaim Sheba Medical Center, Tel Aviv, Israel.

5Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Komaraiah Palle

3Texas Tech University Health Sciences Center, Lubbock, Texas.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Komaraiah Palle

Charles J. Yeo

1The Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.

2Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

William H. Gmeiner

6Deparment of Cancer Biology, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, North Carolina.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: brodyj@ohsu.edu bgmeiner@wakehealth.edu

Jonathan R. Brody

7Department of Surgery and Cell, Developmental and Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: brodyj@ohsu.edu bgmeiner@wakehealth.edu

DOI: 10.1158/1541-7786.MCR-20-0985 Published April 2021

Article
Figures & Data
Info & Metrics
PDF

This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.

Log in using your username and password

Username *

Password *

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

PreviousNext

April 2021
Volume 19, Issue 4

Table of Contents
Table of Contents (PDF)
About the Cover
Editorial Board (PDF)

Search for this keyword

View this article with LENS

Open full page PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition

Message Subject (Your Name) has forwarded a page to you from Molecular Cancer Research

Message Body (Your Name) thought you would be interested in this article in Molecular Cancer Research.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition

Alex O. Haber, Aditi Jain, Chinnadurai Mani, Avinoam Nevler, Lebaron C. Agostini, Talia Golan, Komaraiah Palle, Charles J. Yeo, William H. Gmeiner and Jonathan R. Brody

Mol Cancer Res April 1 2021 (19) (4) 565-572; DOI: 10.1158/1541-7786.MCR-20-0985

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition

Alex O. Haber, Aditi Jain, Chinnadurai Mani, Avinoam Nevler, Lebaron C. Agostini, Talia Golan, Komaraiah Palle, Charles J. Yeo, William H. Gmeiner and Jonathan R. Brody

Mol Cancer Res April 1 2021 (19) (4) 565-572; DOI: 10.1158/1541-7786.MCR-20-0985

Share This Article: